Company news
Galmed Pharmaceuticals Ltd. news in 2021
Galmed Pharmaceuticals Ltd.'s news releases, calls and decks from 2021, newest first.
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
November 7, 2021
Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
November 7, 2021
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
October 31, 2021
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
August 18, 2021
MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
August 15, 2021
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 4, 2021
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
August 1, 2021
Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5
July 28, 2021
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
May 12, 2021
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
May 2, 2021
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
March 17, 2021
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
March 15, 2021
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
March 10, 2021
Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
February 15, 2021
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
February 15, 2021
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
January 25, 2021
Calls in 2021
Decks in 2021
- Technical Presentation (November 2021)
Technical · 13 slides · Nov 8, 2021
- Investor Day (January 2021)
Investor day · 42 slides · Jan 26, 2021